Report from the 20th Conference on Retroviruses and Opportunistic Infections
HIV/AIDS Clinical Care Meeting Report
Free Article
Our physician-editors highlight the most clinically relevant findings from the 2013 meeting in Atlanta.
No Major Breakthroughs in Biomedical Prevention
HIV/AIDS Clinical Care Meeting Report
Subscription Required
Results presented at CROI 2013 underscore some of the barriers to pre-exposure prophylaxis.
The Road to HIV Cure: Twists and Turns
HIV/AIDS Clinical Care Meeting Report
Subscription Required
At CROI 2013, presentations encompassed a range of topics, from possible cure in an infant to sobering data on the size of the HIV reservoir.
HCV Treatment — On the Threshold
HIV/AIDS Clinical Care Meeting Report
Subscription Required
Interferon-free regimens stole the show.
Improving ART — the Pipeline Remains Open in 2013
HIV/AIDS Clinical Care Meeting Report
Subscription Required
At CROI 2013, investigators presented findings from a phase III study of dolutegravir, clinical data on tenofovir alafenamide (TAF), and initial data on a new NNRTI (MK-1439).
Progress in Understanding and Addressing the HIV Cascade of Care
HIV/AIDS Clinical Care Meeting Report
Subscription Required
Encouraging data were presented at CROI 2013, but many challenges remain.
Causes of Death Changing in HIV
HIV/AIDS Clinical Care Meeting Report
Subscription Required
Although AIDS remains the leading cause of death in HIV-infected individuals in developed countries, deaths from non–AIDS-defining malignancies are creeping upward, according to a study presented at AIDS 2012.
HIV and Accelerated Aging: Stay Tuned
HIV/AIDS Clinical Care Meeting Report
Subscription Required
Many chronic conditions traditionally associated with aging occur prematurely in HIV-positive patients, according to data presented at AIDS 2012.
The Cascade of HIV Care in the U.S.
HIV/AIDS Clinical Care Meeting Report
Subscription Required
Only 25% of HIV-infected people in the U.S. achieve virologic suppression, and that number is even lower for racial/ethnic minorities, according to data presented at AIDS 2012.
The Trade-Offs of Branded Versus Generic First-Line ART
HIV/AIDS Clinical Care Meeting Report
Subscription Required
A modeling analysis presented at AIDS 2012 indicated that switching patients from a branded regimen to a predominantly generic one would decrease annual HIV treatment costs in the U.S. by almost one billion dollars but would result in a modest decrease in estimated survival.
